Ala5-galanin (2-11) is a GAL2R specific galanin analogue
- Neuropeptides. 2016 Dec:60:75-82. doi: 10.1016/j.npep.2016.08.008.
- 1. Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 16B, SE-10691 Stockholm, Sweden. Electronic address: [email protected].
- 2. Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 16B, SE-10691 Stockholm, Sweden.
- 3. Research Program for Receptorbiochemistry and Tumormetabolism, Laura Bassi Centre of Expertise THERAPEP, Department of Pediatrics, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, A-5020 Salzburg, Austria.
- 4. Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
- 5. Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 16B, SE-10691 Stockholm, Sweden; Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
It is over 30years since the regulatory peptide Galanin was discovered by Professor Mutt and co-workers. Galanin exerts its effects by binding to three Galanin G-protein coupled receptors, namely GAL1R, GAL2R and GAL3R. Each Galanin receptor has a different distribution in the central nervous system and the peripheral nervous system as well as distinctive signaling pathways, which implicates that the receptors are involved in different biological- and pathological effects. The delineation of the galaninergic system is however difficult due to a lack of stable, specific Galanin receptor ligands. Herein, a new short GAL2R specific ligand, Ala5-galanin (2-11), is presented. The Galanin (2-11) modified analogue Ala5-galanin (2-11) was tested in 125I-galanin competitive binding studies for the three Galanin receptors and the G-protein coupled receptor signaling properties was tested by the ability to influence second-messenger molecules like inositol phosphate and cyclic adenosine monophosphate. In addition, two different label-free real-time assays, namely EnSpire® based on an optical biosensor and xCELLigence® based on an electric biosensor, were used for evaluating the signaling properties using cell lines with different levels of receptor expression. Ala5-galanin (2-11) was subsequently found to be a full agonist for GAL2R with more than 375-fold preference for GAL2R compared to both GAL1R and GAL3R. The single amino acid substitution of serine to alanine at position 5 in the short ligand Galanin (2-11) resulted in a ligand subsequently unable to bind neither GAL3R nor GAL1R, even at concentrations as high as 0.1mM.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Neuropeptide Y ReceptorResearch Areas: Neurological Disease